Description
Rezurock (belumosudil) is an immune and autoimmune medications agent listed in our Immune and autoimmune medications directory and prescribed for conditions within immune and autoimmune medications (1.1) (2.1). Administered via the oral route, Rezurock is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.
Rezurock is a medication containing the active pharmaceutical ingredient belumosudil, classified pharmacologically as an immune and autoimmune medications agent (2.1). It is clinically indicated for the management of conditions within immune and autoimmune medications as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).
Within the Immune and autoimmune medications section of our catalogue, patients and prescribers frequently review Rezurock alongside related therapies such as Advagraf (Tacrolimus), Arava (Leflunomide), Azathioprine, and Calcort (Deflazacort).
Official Indications and Usage
Rezurock is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. (1.1)
Mechanism of Action and Pharmacology
Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (rock) which inhibits ROCK2 and ROCK1 with IC 50 values of approximately 100 nM and 3 µM, respectively. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or in vitro -human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, in vitro. In vivo, belumosudil demonstrated activity in animal models of chronic GVHD. (1.1)
Ordering Rezurock from Canada for U.S. Delivery
U.S. patients can order Rezurock (Belumosudil) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.
Step 1
Send Your Prescription
- Valid Rx required from a U.S.-licensed physician, NP, or PA (Rx rules).
- Upload Rx online, request a pharmacy transfer, or have your doctor fax (844) 666 – 6819.
- Order up to a 90-day personal-use supply per shipment (refill planning).
Step 2
Pharmacist Safety Check
- Multi-point dosing and interaction review completed in under 1 business day.
- Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
- Verified under our Pharmacy Safety Standards.
Step 3
$14.99 USD Tracked Parcel
- Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
- Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
- Review full shipping and delivery details.
Step 4
U.S. Street Delivery & Payment
- Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
- You see and approve the country of origin upfront before your card is charged.
- Report any delayed or damaged parcel within 48 hours for prompt resolution.
Fact Table
| Clinical Specification | Details |
|---|---|
| Brand / Product Name | Rezurock |
| Chemical / Generic Name | Belumosudil |
| Pharmacological Class | Immune and autoimmune medications agent |
| Therapeutic Category | Immune and autoimmune medications |
| Molecular Weight | 548.62 g/mol (2.1) |
| Bioavailability | ~64% (1.1) |
| Elimination Half-Life | ~19 hours (1.1) |
| Legal Status | Rx-Only (Prescription Required) |
| Regulatory Reference Authorities | U.S. FDA (DailyMed), Health Canada (DPD) |
| Routes of Administration | Oral |
| Dosage Forms & Strengths | Each 200 mg belumosudil tablet is a pale yellow film-coated oblong tablet debossed with "kdm" on one side and "200" on the other side. Tablet: 200 mg |
| Primary Indications | Conditions Within Immune And Autoimmune Medications |
| Pregnancy & Breastfeeding | Consult Doctor / Prescriber before use |
| FDA UNII Identifier | 834YJF89WO |
| NLM RxNorm Concept ID (RxCUI) | 2564031, 2564037 |
| FDA Application License | NDA214783 |
| Official DailyMed SetID | 102e4ef4-7f84-4e34-8df1-479c24d1575d |
| Catalogue Index Links | Letter R Index · All Medications · All Categories |
Directions
Dosage and Administration Overview
Recommended Dosage: 200 mg taken orally once daily with food. 2.1 Recommended Dosage The recommended dose of Rezurock is 200 mg given orally once daily until progression of chronic GVHD that requires new systemic therapy. Instruct the patient on the following: Swallow Rezurock tablets whole. Do not cut, crush, or chew tablets. Take Rezurock with a meal at approximately the same time each day. (1.1)
Presentations and Strengths
Each 200 mg belumosudil tablet is a pale yellow film-coated oblong tablet debossed with "kdm" on one side and "200" on the other side. Tablet: 200 mg. (1.1)
Administration Guidance
Take Rezurock orally at the same time(s) each day as directed on your prescription label (1.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.
Missed Dose Guidance
If you miss a scheduled dose of Rezurock, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).
Ingredients
Active Pharmaceutical Ingredient
The active ingredient in Rezurock is belumosudil (2.1).
Inactive Ingredients (Excipients)
According to the U.S. FDA product labeling, formulation excipients include colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate, and microcrystalline cellulose (1.1). Inactive ingredients can vary slightly between different manufacturers and international or generic presentations; review the dispensed carton if you have known excipient sensitivities.
Cautions and important safety information
Contraindications
None. (1.1)
Key Clinical Precautions
Before starting or continuing Rezurock, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):
- Fetal toxicity and pregnancy considerations: This medication may cause fetal harm when administered to a pregnant patient. Discuss pregnancy planning, effective contraception, and safe treatment alternatives with your healthcare provider.
Pregnancy, Lactation, and Special Populations
Based on findings from animal studies and the mechanism of action, Rezurock can cause fetal harm when administered to pregnant women. There are no available human data on Rezurock use in pregnant women to evaluate for a drug-associated risk. In animal reproduction studies, administration of belumosudil to pregnant rats and rabbits during the period of organogenesis resulted in adverse developmental outcomes, including alterations to growth, embryo-fetal mortality, and embryo-fetal malformations at maternal exposures (AUC) approximately ≥1.4 (rat) and ≥0.08 (rabbit) times the human exposure (AUC) at the recommended dose. (1.1)
Interactions
Official Drug Interaction Overview
Strong CYP3A Inducers: Increase Rezurock dosage to 200 mg twice daily. Proton Pump Inhibitors: Increase Rezurock dosage to 200 mg twice daily. BCRP Substrates: Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions and decrease the substrates dosage(s) in accordance with the respective Prescribing Information. Certain CYP1A2, CYP3A, P-gp or UGT1A1 Substrates: Avoid concomitant use with these substrates for which minimal concentration changes may lead to serious toxicities. (1.1)
Important Interaction Categories
Concomitant use of Rezurock with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):
- Strong CYP3A4 inhibitors and inducers (such as ketoconazole, itraconazole, clarithromycin, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort): Co-administration with strong CYP3A4 inhibitors can significantly increase plasma concentrations and side-effect risk, whereas CYP3A4 inducers can decrease systemic exposure and reduce efficacy.
Side effects
Like all medications, Rezurock can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):
- Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; taking oral doses with food (when permitted by the label) may help.
- Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
- Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
- Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
- Abdominal discomfort or stomach pain: Mild gastrointestinal upset may occur; report severe, persistent, or radiating abdominal pain promptly.
- Fatigue or tiredness: May occur during initial adjustment or dose changes.
Clinical Trial and Postmarketing Adverse Reactions
The most common (≥20%) adverse reactions, including laboratory abnormalities, are infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension. Because clinical trials are conducted under widely variable conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice. Chronic Graft versus Host Disease In two clinical trials (Study KD025-213 and Study KD025-208), 83 adult patients with chronic GVHD were treated with Rezurock 200 mg once daily. The median duration of treatment was 9.2 months (range 0.5 to 44.7 months). (1.1)
When to Seek Immediate Medical Attention
Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).
Storage and handling
Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). Dispense to patient in original container only. Store in original container to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant. (1.1)
Store Rezurock in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).
Frequently Asked Questions About Rezurock
What is Rezurock and what active ingredient does it contain?
Rezurock is an immune and autoimmune medications agent containing the active pharmaceutical ingredient belumosudil. It is supplied for oral administration and requires a valid prescription where applicable.
How does Rezurock work in the body?
Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (rock) which inhibits ROCK2 and ROCK1 with IC 50 values of approximately 100 nM and 3 µM, respectively. Belumosudil down-regulated proinflammatory responses via regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in ex-vivo or in vitro -human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, in vitro.
What conditions is Rezurock prescribed to treat?
Rezurock is primarily indicated for conditions within immune and autoimmune medications. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.
How should I take or use Rezurock?
Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Rezurock is administered via the oral route. Take it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.
What are the most common side effects of Rezurock?
Commonly reported side effects of Rezurock include feeling sick, vomiting, loose stools, headache, abdominal pain, and tiredness. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.
What medications or substances can interact with Rezurock?
Important interaction categories for Rezurock include medicines that strongly affect CYP3A enzymes. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.
Can Rezurock be used during pregnancy or breastfeeding?
Official prescribing information highlights pregnancy-related precautions for Rezurock. Inform your healthcare provider immediately if you are pregnant, planning to become pregnant, or breastfeeding so safe treatment options can be evaluated.
Do I need a prescription to buy Rezurock online from Canada?
Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Rezurock (Belumosudil) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).
Does Rezurock have a generic equivalent (Belumosudil) at a Canada pharmacy?
Currently, Rezurock (Belumosudil) is dispensed in our catalogue as a brand-name formulation. Check our Belumosudil active ingredient hub for updates as licensed generic presentations become available.
How is Rezurock shipped to U.S. residents, and how much does shipping cost?
Rezurock ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.
How can I send or transfer my Rezurock prescription, or ask about an unlisted strength?
You can upload a clear photo or PDF of your Rezurock prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.
References & Official Sources
Clinical, pharmacological, and safety facts for Rezurock (Belumosudil) are compiled directly from official regulatory prescribing labels and primary biomedical databases:
- (1.1) Rezurock. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
- (2.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).
